Effects of a specific thromboxane synthetase inhibitor on thromboxane generation and excretion in healthy dogs.
A specific thromboxane synthetase inhibitor, 3-methyl-2 (3-pyridyl)-1-indoleoctanoic acid (CGS 12970) was administered orally to 6 healthy adult Beagles at a dosage of 30 mg/kg of body weight. Blood generation of thromboxane B2 and urinary excretion of thromboxane B2 were measured before and after administration of CGS 12970. Although 97 +/- 0.4% inhibition of thromboxane B2 generation was observed within 2 hours after a single dose of CGS 12970 was administered orally, an effect on urinary excretion of thromboxane B2 was not observed. Additionally, oral administration of 30 mg/kg every 12 hours resulted in 80 +/- 14% inhibition of thromboxane B2 generation but had no effect on urinary thromboxane B2 excretion.
Longhofer
S L
SL
Department of Medical Sciences, School of Veterinary Medicine, University of Wisconsin, Madison 53706.
Johnson
H C
HC
Culham
C A
CA
Schultz
K T
KT
Grauer
G F
GF
D000284:Administration, Oral; D000818:Animals; D004285:Dogs / Q000097:blood / Q000378:metabolism*; D007668:Kidney / Q000201:enzymology; D008297:Male; D011725:Pyridines / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology* / Q000652:urine; D013929:Thromboxane B2 / Q000096:biosynthesis* / Q000097:blood / Q000652:urine; D013930:Thromboxane-A Synthase / Q000378:metabolism* / Q000494:pharmacology; D013997:Time Factors
D011725:Pyridines; D013929:Thromboxane B2; C049113:3-methyl-2-(3-pyridyl)-1-indoleoctanoic acid; D013930:Thromboxane-A Synthase